Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Capital Expenditures (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Capital Expenditures data on record, last reported at -$189000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 34.83% year-over-year to -$189000.0; the TTM value through Sep 2025 reached -$101000.0, down 115.37%, while the annual FY2024 figure was $58000.0, 85.99% down from the prior year.
  • Capital Expenditures reached -$189000.0 in Q4 2025 per CTNM's latest filing, down from $98000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $309000.0 in Q4 2023 and bottomed at -$290000.0 in Q4 2024.
  • Average Capital Expenditures over 3 years is $39333.3, with a median of $49500.0 recorded in 2023.
  • The widest YoY moves for Capital Expenditures: up 283.87% in 2024, down 193.85% in 2024.
  • A 3-year view of Capital Expenditures shows it stood at $309000.0 in 2023, then crashed by 193.85% to -$290000.0 in 2024, then surged by 34.83% to -$189000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$189000.0 in Q4 2025, $98000.0 in Q3 2025, and $44000.0 in Q2 2025.